You are here: Home » Current Affairs » Coronavirus » News
Business Standard

RDIF, Dr Reddy's to cooperate on trials, distribution of Sputnik V vaccine

The Russian Direct Investment Fund (RDIF), Russias sovereign wealth fund, and Dr Reddys Laboratories Ltd have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India

Topics
Coronavirus Vaccine | Russia | Coronavirus

Press Trust of India  |  Hyderabad 

Coronavirus, vaccine, covid

The Russian Direct Investment

Fund (RDIF), Russias sovereign wealth fund, and Dr Reddys Laboratories Ltd. have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India.

Upon regulatory approval in India, RDIF shall supply to Dr. Reddys 100 million doses of the vaccine, Dr Reddys said in a release on Wednesday.

The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the pandemic, it said.

Deliveries could potentially begin in late 2020, subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, the release said.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said RDIF is very pleased to partner with Dr. Reddys in India.

Dr. Reddys has had a very well established and respected presence in for over 25 years and is one of the leading pharmaceutical companies in India, he said.

"India is amongst most severely impacted countries from COVID-19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID 19," the release quoted Dmitriev as saying.

RDIF partners will receive an effective and safe drug to fight the The platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences, Dmitriev said.

G V Prasad, Co-Chairman and Managing Director of Dr. Reddys Laboratories said his company is pleased to partner with RDIF to bring the vaccine to India.

"The Phase I and II clinical trials have shown promising results. We will be conducting Phase-III trials in India to ensure safety and efficacy for the Indian population and to meet the requirements of the Indian regulators.

Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India, he said.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of and became the worlds first registered vaccine against COVID-19 based on the human adenoviral vectors platform, the release said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 16 2020. 18:46 IST
RECOMMENDED FOR YOU
.